Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 19Thoracic 2Plasma cell 2Other hematologic neoplasm 2Head & Neck 2Gastrointestinal 2Dermatologic 2Breast 2NET 1Lymphoid 1Gynecologic 1Endocrine 1Classical hematology 1

Conditions

Colorectal Neoplasms 1463Pancreatic Neoplasms 833Stomach Neoplasms 692Carcinoma, Hepatocellular 647Carcinoma, Non-Small-Cell Lung 542Neoplasms 459Breast Neoplasms 369Ovarian Neoplasms 338Neoplasm Metastasis 337Colonic Neoplasms 332Esophageal Neoplasms 297Liver Neoplasms 266Melanoma 255Lung Neoplasms 246Squamous Cell Carcinoma of Head and Neck 210Cholangiocarcinoma 180Carcinoma, Renal Cell 180Prostatic Neoplasms 175Head and Neck Neoplasms 172Triple Negative Breast Neoplasms 163Rectal Neoplasms 160Endometrial Neoplasms 160Uterine Cervical Neoplasms 155Gastrointestinal Neoplasms 142Urinary Bladder Neoplasms 139Biliary Tract Neoplasms 135Gastrointestinal Stromal Tumors 108Sarcoma 105Esophageal Squamous Cell Carcinoma 102Small Cell Lung Carcinoma 95

Interventions

Pharmaceutical Preparations 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Kidney Diseases × Gastrointestinal × Clear all
NCT00753415 2015-03-17

A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

Merck Sharp & Dohme LLC

Phase 1 Completed
37 enrolled 10 charts
BreastDermatologicEndocrineGastrointestinalGenitourinaryNETThoracic

Adenocarcinoma, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Breast Diseases, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Genital Diseases, Male, Intestinal Neoplasms, Kidney Diseases, Kidney Neoplasms, Melanoma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Prostatic Diseases, Prostatic Neoplasms, Skin Diseases, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Colorectal Neoplasms, Neuroectodermal Tumors, Nevi and Melanomas, Neuroendocrine Tumors

NCT00035334 2006-02-14

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Bellus Health Inc. - a GSK company

Phase 2/3 Completed
150 enrolled
GastrointestinalGenitourinaryPlasma cell

Amyloidosis, Arthritis, Rheumatoid, Gastrointestinal Diseases, Kidney Diseases, Neoplasm Metastasis, Nephrotic Syndrome, Familial Mediterranean Fever

Data powered by HemOnc (CC BY 4.0) Colophon âš¡